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Summary Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer
although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less
clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in
normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast
cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of
follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months.
There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-
menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This
study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to
affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short
(maximum 36 months) and careful long term follow-up is necessary to detect clinically significant mor-
bidity.
Tamoxifen is widely used as adjuvant therapy in early breast
cancer and overview analysis of randomised tamoxifen trials
has demonstrated a prolongation of the disease-free interval
and an overall survival advantage for patients receiving
tamoxifen (EBCTCG, 1992; MacDonald et al., 1991).
Although tamoxifen is well tolerated with a low level of acute
side effects, the optimum duration of treatment is unclear
and there has only been limited data on long term side-effects
(Powles et al., 1989; 1990). Tamoxifen has both oestrogen
agonist and antagonist properties which are organ and
species specific, however, concern has been raised about
oestrogen antagonist activity and long term adverse effects,
for example on coagulation, lipid profile and cardiovascular
pathology (Fox et al., 1981). A number of anecdotal reports
have suggested that tamoxifen therapy is associated with an
increased risk of thromboembolic events in patients with
advanced breast cancer (Lipton et al., 1984; Nevasaari et al.,
1978; Hendrick & Subramanian 1980; Dahan et al., 1985),
however it is difficult to evaluate the contribution of tamox-
ifen to thrombosis in these patients because of the generally
increased risk of thrombosis in cancer patients per se. For
patients receiving tamoxifen as adjuvant therapy, the position
is even less clear. The frequency of arterial or venous throm-
bosis has been reported to be 5.4% among patients who
received adjuvant therapy compared with 1.6% in patients on
observation in a retrospective review of 2,673 patients (Saph-
ner et al., 1991). The risk ofthrombosis was highest for those
patients receiving tamoxifen together with chemotherapy
(Saphner et al., 1991) but tamoxifen as monotherapy was
only associated with a marginal, if any, increase in throm-
boembolic events (Saphner et al., 1991; Fornander et al.,
1991) and indeed it has been suggested that adjuvant tamox-
ifen may have a beneficial effect on thrombosis with a reduc-
tion in cardiovascular deaths (EBCTCG, 1992; MacDonald
et al., 1991).
We have investigated the effects of tamoxifen on coagula-
tion parameters in normal healthy women who had been
entered into a double-blind placebo controlled trial of tamox-
ifen as a chemopreventative agent in breast cancer (Powles et
al., 1989; 1990). Fibrinogen, a major predictor of cardiovas-
cular risk factor and cross linked fibrin degradation products
to detect increases in fibrinolysis were measured (EBCTCG,
1992; MacDonald et al., 1991). Antithrombin III, which
inhibits thrombin and other activated clotting factors, and
Protein C and Protein S which are important natural
inhibitors of coagulation (Esmon, 1987) were also assayed as
deficiencies of these factors may lead to a hypercoaguable
state and increased risk of thromboembolic events.
Patients, materials and methods
Normal healthy pre and postmenopausal women with a
positive maternal history of breast cancer were enrolled in a
double-blind placebo controlled pilot trial investigating the
use of tamoxifen as a chemopreventative agent in breast
cancer. The details of this trial haved been described
previously (Powles et al., 1989; 1990). Patients with a history
of venous thrombosis or pulmonary embolism were excluded.
Patients were prescribed 'tamoplac' and randomised in a
double-blind fashion to receive tamoxifen 20mg/day or a
placebo of identical appearance. A total of 515 patients had
pretreatment blood samples taken for fibrinogen and anti-
thrombin III assays and samples were repeated on treatment
at 6 monthly intervals. A subset of 39 consecutive patients
had pretreatment and on-treatment samples at 6 months for
Protein C, Protein S and cross linked fibrin degradation
products (XL-FDP).
Assays
Antithrombin III and Fibrinogen
Antithrombin III (AT3) and plasma fibrinogen were assayed
using functional photometric assays with the Cobus Mira
and kits supplied by Boehringer Mannheim (Kit 759 376 for
AT3 and Kit 524484 for fibrinogen). The methodology and
principle for the AT3 assay is described by Becker et al.
(Becker et al., 1984) and for fibrinogen by Hesse et al. (1981).
The normal range for AT3 was 20-291 U ml-' and for
fibrinogen 140-450 mg dl-'.
Protein C and Protein S
Protein C and Protein S antigen (bound and free) were
measured by enzyme linked immunosorbent assay) using
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peroxidase-conjugated rabbit anti-human Protein C and anti-
human Protein S polyclonal antibodies. (Dako Ltd, High
Wycombe, Buckinghamshire) (Avameas & Ternycke, 1971;
Woodhams, 1988).
The normal range for Protein C was 70-130 IU dl-' and
for Protein S normal range was 70-130% pooled normal
plasma.
Crosslinkedfibrin degradation products (XL-FDP)
XL-FDP were measured by an immunoassay (Dimertest
Enzyme Immunoassay supplied by Porton Cambridge Ltd,
Maidenhead, Berkshire). The method employs a monoclonal
antibody which recognises D-dimer and fragments containing
the D-dimer epitope (Rylatt et al., 1988) (normal range
<250 ng ml-').
Statistics
Results have been analysed for each treatment group as a
whole and separately for pre and postmenopausal women
and expressed as a percentage of the pretreatment value
(± s.e.m.) for each group. The t-test was used to assess the
significance of the change from the pretreatment value at
each 6 monthly time point.
Results
For premenopausal women there was a reduction in plasma
fibrinogen levels at 6 months on tamoxifen to 90% (± 7%)
of pretreatment values (P<0.005) and this fall was sustained
over the first year of follow-up (P<0.001) (Figure la). This
represents a mean fall in fibrinogen of 28 mgdl-'. For post-
menopausal women there was a similar reduction to 85%
(± 5%) of pretreatment values (P<0.001) sustained over the
first year (P<0.02) representing a mean fall of 46mgdl-'
(Figure lb). After 12 months there was no apparent
difference in fibrinogen levels but numbers ofpatients at each










There was no reduction in antithrombin 3 on treatment for
premenopausal women (Figure 2b), however there was a
reduction in antithrombin 3 for postmenopausal women
(Figure 2a) to 96% ± 3% of pretreatment values at 12
months (P<0.05).
For premenopausal women there was no change in Protein
S antigen or Protein C on treatment (Figure 3). For post-
menopausal women there was an overall marginal reduction
in Protein antigen to 90% of pretreatment levels at 6 months
(P = 0.05) but no change in Protein C levels (Figure 4). No
subject had pretreatment. values of Protein C or Protein S
antigen below 50% of the normal range. There were no
significant changes in crosslinked FDP's for either pre or
postmenopausal women on treatment with no value outside
the normal range (250 mgml-').
No thromboembolic events have been recorded so far in
either arm.
Discussion
Tamoxifen has been implicated as a risk factor for throm-
boembolic disease however the only evidence for this has
come from reports of patients with advanced disease in
whom the presence of a hypercoaguable state may be mul-
tifactorial. This study has allowed evaluation of tamoxifen on
coagulation factors in a placebo controlled trial in a popula-
tion of normal women. Although the reduction in fibrinogen
was no longer apparent after 12 months, this may be a
reflection of low patient numbers at the later time points.
Fibrinogen, the plasma precursor of fibrin, is recognised as
an important factor in the pathogenesis of arterial throm-
botic disease and increased plasma levels are a major risk
factor for ischaemic heart disease independent of the in-
creased risk associated with high plasma cholesterol concen-
tration (Becker et al., 1984; Lowe et al., 1991). In this study
in normal women there was no increase in fibrinogen levels
and indeed for both pre and postmenopausal women on
tamoxifen there was a significant reduction in fibrinogen
levels. This reduction was sustained over the first year of
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Figure 1 Change in fibrinogen on tamoplac expressed as a
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Figure 2 Antithrombin III levels on tamoplac expressed as a
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Figure 4 Protein S antigen levels




follow-up and therefore cannot be explaine
variation in fibrinogen levels (Stout & Crawfc
fall in fibrinogen did not appear to be relate
fibrinolysis as there were no changes in crc
degradation products for either pre or p
women (Lane et al., 1978).
Blood coagulation is controlled by two m
pathways, antithrombin III and the protei
(Esmon, 1987). Antithrombin III is the
inhibitor of the thrombin activated pathw;
deficiency of antithrombin III to levels betwee
of normal controls has been associated with
quency of thrombotic episodes (Tabernero
Decreases in antithrombin III have been repoi
treated with tamoxifen for advanced disease
1984) or as adjuvant therapy in node positiv(
(Jordan et al., 1987) but these reductions were
and therefore not down to the level at whic
risk of thrombosis might be expected. In our s
no reduction in antithrombin III for premenc
and only a small reduction (<10%) in p
women. The findings with tamoxifen are in (
oral contraceptive pill which is associated witb
fibrinogen levels and a replacement therapy
pausal women in whom a significant decrease i
III has also been reported (Boschetti et al.,
Protein C is a hepatic vitamin K dependent
when activated, inhibits coagulation by inacti
and VIII (Esmon, 1987). This occurs wher
activated on the endothelial cell surface by ti
to thrombomodulin. Protein S is an essential
binds to Protein C for this reaction to be o0
1987). Inherited deficiency of either Protein C or S is
associated with an increased incidence of deep vein throm-
bosis although the overall prevalence of deficiency of anti-
thrombin III, Protein C or S in patients with recurrent
thrombosis is only 8.3% (Tabernero, 1991; Heijboer, 1990).
In our study there was no reduction in Protein C at 6 months
and there was only a marginal reduction in Protein S in
postmenopausal patients. Although congenital Protein S
deficiency is a risk factor for venous thrombosis and has also
been implicated as a risk factor for arterial thrombosis
(Wiessel, 1991), the marginal reduction (10%) in this study is
not of the order associated with clinical problems. These
ao' marginal changes are comparable with those reported in
c postmenopausal women on continous oestradiol-progestogen
hormone replacement therapy in whom there was also a
as a percentage trend towards a reduction in Protein C (Sporrong, 1990) and
support an oestrogen agonist action of tamoxifen.
Although these results for proteins C and S are reported
after 6 months of treatment and longer follow-up may reveal
further changes with time, our experience with fibrinogen and
antithrombin III levels on tamoxifen suggests that the pattern
seen at 6 months is sustained with time. This stable pattern is
in keeping with the observation that tamoxifen metabolites in
patients on long-term adjuvant tamoxifen are also stable with
time (Langan-Fahey, 1991).
The potential increased risk of venous or arterial throm-
bosis previously reported with tamoxifen therapy may be
mainly related to an inherent increased thrombotic tendency
in patients with advanced breast cancer. For patients receiv-
ing adjuvant tamoxifen as monotherapy for early breast
cancer there is if anything, only a marginal increase in
thromboembolic events (Saphner et al., 1991; Fornander et
al., 1991), comparable with the increased risk associated with
Placebo hormone replacement therapy. This possible marginal risk
I-C
has been deemed acceptable in view of the favourable impact
of tamoxifen on disease-free and overall survival (EBCTCG,
expressed as a 1992; MacDonald et al., 1991). If the use of tamoxifen is
extended as adjuvant therapy node negative breast cancer
and in particular if tamoxifen is used as a chemopreventative
agent in normal women, then any thromboembolic risk fac-
tors and long-term safety become of increasing importance.
d by seasonal Previous reports have shown significant reduction in choles-
:rd, 1991). The terol, and fasting low density lipoprotein cholesterol in
.d to increased normal women receiving tamoxifen in this pilot chemopre-
)sslinked fibrin vention trial (Powles et al., 1989; 1990). The findings in this
)ostmenopausal study favour oestrogen agonist, rather than antagonist activ-
ity of tamoxifen and such changes may contribute to the
ajor regulatory observed reduction in deaths from ischaemic heart disease in
in C pathway women receiving adjuvant tamoxifen (EBCTCG, 1992; Mac-
major natural Donald et al., 1991). The clinical relevance of the reduction
ay. Congenital in fibrinogen levels in women receiving tamoxifen in this
-n 50 and 70% study is uncertain. The effects of tamoxifen on haemostasis
increased fre- are likely to be multifactorial, however the available evidence
et al., 1991). in normal women does not suggest any likely increase in the
rted in patients risks of arterial or venous thrombosis.
(Enck & Rios, In large scale tamoxifen prevention trials women with a
e breast cancer history of thromboembolic disease should be carefully
less than 30% evaluated before being prescribed long-term tamoxifen, how-
h an increased ever the relatively low incidence of congenital deficiency of
study there was antithrombin III, protein S or C even in this group would
)pausal women not support widespread screening for these factors. Careful
ostmenopausal long-term follow-up of all patients in prevention trials is
contrast to the necessary to detect any clinically significant alteration in the
an increase in incidence of cardiovascular disease or venous thrombosis
in postmeno- although the currently available data suggest that tamoxifen
in antithrombin has only a marginal effect on haemostasis, which is mainly an
1991). oestrogen agonist effect, which would not have an adverse
protein which, clinical impact or cardiovascular risk or venous thrombosis
vating factor V in either pre or postmenopausal women.




We would like to acknowledge Mr A.K. Ray for technical assistance
and Mrs J.A. Fleming for secretarial assistance.
Fn
lz
Ft% tiHAEMOSTATIC CHANGES DURING TAMOXIFEN THERAPY 747
References
AVAMEAS, S. & TERNYCKE, T. (1971). Peroxidase labelled antibody
and conjugates with enhanced intracellular penetration.
Immunochemistry, 8, 1175-1179.
BECKER, U., BART, L.K. & WAHLEFOLD, A.W. (1984). A functional
photometric assay for plasma fibrinogen. Thrombosis Res., 35,
475-484.
BOSCHETTI, C., CORTELLARO, M., NENCIONI, T. BERTOLLI, V.,
DELL-VOLPE, A. & ZANUSSI, C. (1991). Short and long-term
effects of hormone replacement therapy (transdermal estradiol vs
oral conjugated equine estrogens on blood coagulation factors in
postmenopausal women. Thromb. Res, 62, 1-8.
COOK, N.S. & UBBEN, D. (1990). Fibrinogen as a major risk factor in
cardiovascular disease. Trends Pharmcol. Sci., 11, 444-451.
DAHAN, R., ESPIE, H., MIGNOT, C., HOULBERT, D. & CHANU, B.
(1985). Tamoxifen and arterial thrombosis. Lancet, 1, 638.
EARLY BREAST CANCER TRIALIST'S COLLABORATIVE GROUP
(1992). Systemic treatment of early breast cancer by hormonal,
cytotoxic or immune therapy. Lancet, i, 1-15.
ENCK, R.E. & RIOS, C.N. (1984). Tamoxifen treatment of metastatic
breast cancer and antithrombin III levels. Cancer, 53,
2067-2069.
ESMON, C.T. (1987). The regulation of natural anticoagulant path-
ways. Science, 255, 1348-1352.
FORNANDER, T., RUTQUIST, L.E., CEDERMARK, B., GLAS, U.,
MALSTON, A., SKOOG, L., SOMELL, A., THERE, T., WILKING, N.,
ASKERGREN, J., ROLSTEIN, S., HJALMAR, M.-L. & PERBECK, L.
(1991). Adjuvant tamoxifen in early-stage breast cancer: effects
on intercurrent morbidity and mortality. J. Clin. Oncol., 9,
1740-1749.
FOX, G., ADIELSSON, G. & MALTSON, W. (1981). Oestrogen-like
effects of tamoxifen on the concentrations of proteins with
plasma. Acta Endocrinol., 97, 109-113.
HEIJBOER, H., BRANDJES, D.P., BULLER, H.R., STURK, A. & TEN
CAKE, J.W. (1990). Deficiencies of coagulation - inhibiting and
fibrinolytic proteins in outpatients with deep-vein thrombosis.
New Engl. J. Med., 323, 1512-1516.
HENDRICK, A. & SUBRAMANIAN, V.P. (1980). Tamoxifen and
thromboembolism. J. Am. Med. Assoc., 243, 514-515.
HESSE, R. (1981). Blut, 42, 227-234.
JORDAN, V.C., FRITZ, N.F. & TORMEY, D.C. (1987). Long term
adjuvant therapy with tamoxifen: effects on sex binding globulin
and antithrombin III. Cancer Res., 47, 4517-4519.
LANE, D.A., PRESTON, F.E., VAN ROSS, M.R. & KAKKAR, V. (1978).
Characterisation of serum fibrinogen and fibrin fragments pro-
duced during disseminated intravascular coagulation. Br. J.
Haem., 40, 609-615.
LANGAN-FAHEY, S.M., TORMEY, D.C. & JORDAN, V.C. (1991).
Tamoxifen metabolites in patients on long-term adjuvant therapy
for breast cancer. Eur. J. Cancer, 26, 883-888.
LIPTON, A., HARVEY, H. & HAMILTON, K.W. (1984). Venous throm-
bosis as a side-effect of tamoxifen treatment. Cancer Treat. Resp.,
68, 887-889.
LOWE, G.D., WOOD, D.A., DOUGLAS, J.T., RIEMERSMA, R.A.,
MACINTYRE, C.C., TAKASE, T., TUDDENHAM, E.G., FORBES,
C.D., ELTON, R.A. & OLIVER, H.F. (1991). Relationships of
plasma viscosity, coagulation and fibrinolysis to coronary risk
factors and angina. Thromb. Haemost., 65, 339-343.
MACDONALD, C.C., STEWART, H.J., SCOTTISH BREAST CANCER
COMMITTEE (1991). Fata myocardial infarction in the Scottish
adjuvant tamoxifen trial. Br. Med. J., 61, 1316-1319.
NEVASAARI, K., HEIKKINEN, M. & TASKINEN, P.J. (1978). Tamox-
ifen and thrombosis. Lancet, 2, 946-947.
POWLES, T.J., HARDY, J.R., ASHLEY, S.E., FARRINGTON, G.M., COS-
GROVE, D., DAVEY, J.B., DOWSETT, M., MCKINNA, J.A., NASH,
A.G., SINNETT, H.D., TILLYER, C.R. & TRELEAVEN, J.G. (1989).
A pilot trial to evaluate toxicity and feasibility of tamoxifen for
prevention of breast cancer. Br. J. Cancer, 60, 126.
POWLES, T.J., TILLYER, C.R., JONES, A.L., ASHLEY, S.E. &
TRELEAVEN, J. (1990). Prevention of breast cancer with tamox-
ifen - an update on the Royal Marsden Hospital Pilot Prog-
ramme. Eur. J. Cancer, 26, 680-684.
ROBINSON, G.E., BURREN, T., MACKIE, I.J., BOUNDS, W., WALSHE,
K., FAINT, R., GUILBEBAID, J. & MACKIN, S.T. (1991). Changes
in haemostasis after stopping the combined contraceptive pill:
implications for major surgery. Br. Med. J., 302, 269-271.
RYLATT, D.B., BLAKE, A.S., COTTIS, L.E., MASSINGHAM, D.A.,
FLETCHER, W.A., MASCI, P.P., WHITAKER, A.N., ELMS, M.,
BUNCE, I., WEBBER, A.J., WYATT, D. & BUNDEON, P.G. (1988).
An immunoassay for humber D-dimer dusing monoclonal
antibodies. Thrombosis Res., 31, 767-778.
SAPHNER, T., TORMEY, D.C. & GRAY, R. (1991). Venous and
arterial thrombosis in patients who received adjuvant therapy for
breast cancer. J. Clin. Oncol., 9, 286-294.
SPORRONG, T., MALTSON, L.A., SAMSIRE, G., STIGENDAL, L. &
HELLGREN, M. (1990). Haemostatic changes during continuous
oestradiol-progestogen treatment of postmenopausal women. Br.
J. Obstet. Gynaecol., 93, 939-944.
STOUT, R.W. & CRAWFORD, V. (1991). Seasonal variations in
fibrinogen concentrations among elderly people. Lancet, 338,
9-15.
TABERNERO, M.D., TOMAS, J.F., ALBERCA, I., ORFAO, A., LOPEZ-
BORRASCA, A. & VICENTE, V. (1991). Incidence and clinical
characteristics of hereditary disorders associated with venous
thrombosis. Am. J. Haematol., 36, 249-254.
WIESSEL, M.L., BORG, J.Y., GRUNEBAUM, L., VASSE, M., LEVES-
QUE, H., BIERME, R. & SIE, P. (1991). Influence of protein S
deficiency on the arterial thrombosis risk. Presse Med., 20,
1023-1027.
WOODHAMS, B.J. (1988). The simultaneous measurement of total
and free Protein S by ELISA. Thrombosis Res., 50, 213-220.